Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance.

Federer-Gsponer JR, Quintavalle C, Müller DC, Dietsche T, Perrina V, Lorber T, Juskevicius D, Lenkiewicz E, Zellweger T, Gasser T, Barrett MT, Rentsch CA, Bubendorf L, Ruiz C.

J Pathol. 2018 May;245(1):74-84. doi: 10.1002/path.5052. Epub 2018 Apr 2.

PMID:
29484655
2.

Donor-derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus.

Müller DC, Rämö M, Naegele K, Ribi S, Wetterauer C, Perrina V, Quagliata L, Vlajnic T, Ruiz C, Balitzki B, Grobholz R, Gosert R, Ajuh ET, Hirsch HH, Bubendorf L, Rentsch CA.

J Pathol. 2018 Mar;244(3):265-270. doi: 10.1002/path.5012. Epub 2018 Feb 1.

PMID:
29205775
3.

The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.

Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, Grode L, Kaufmann SHE.

Front Immunol. 2017 Sep 19;8:1147. doi: 10.3389/fimmu.2017.01147. eCollection 2017. Review.

4.

Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?

Rentsch CA, Müller DC, Ruiz C, Bubendorf L.

Eur Urol. 2017 Dec;72(6):960-961. doi: 10.1016/j.eururo.2017.06.022. Epub 2017 Jul 5. No abstract available.

PMID:
28688612
5.

ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.

Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derré L.

J Clin Invest. 2017 Aug 1;127(8):2916-2929. doi: 10.1172/JCI89717. Epub 2017 Jun 26.

6.

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, Attard G, Cross W, Jones RJ, Parker CC, Russell JM, Thalmann GN, Schiavone F, Cassoly E, Matheson D, Millman R, Rentsch CA, Barber J, Gilson C, Ibrahim A, Logue J, Lydon A, Nikapota AD, O'Sullivan JM, Porfiri E, Protheroe A, Srihari NN, Tsang D, Wagstaff J, Wallace J, Walmsley C, Parmar MKB, Sydes MR; STAMPEDE Investigators.

J Clin Oncol. 2017 May 10;35(14):1530-1541. doi: 10.1200/JCO.2016.69.0677. Epub 2017 Mar 13.

7.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.

Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.

8.

Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer.

Rentsch CA, Müller DC, Ruiz C, Bubendorf L.

Eur Urol. 2016 Jul;70(1):83-84. doi: 10.1016/j.eururo.2016.02.050. Epub 2016 Mar 4. No abstract available.

PMID:
26951946
9.

Dynamics of Urinary Calprotectin after Renal Ischaemia.

Ebbing J, Seibert FS, Pagonas N, Bauer F, Miller K, Kempkensteffen C, Günzel K, Bachmann A, Seifert HH, Rentsch CA, Ardelt P, Wetterauer C, Amico P, Babel N, Westhoff TH.

PLoS One. 2016 Jan 8;11(1):e0146395. doi: 10.1371/journal.pone.0146395. eCollection 2016.

10.

Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep.

Rentsch CA, Stenner F, Ruiz C, Bubendorf L.

Eur Urol. 2015 Dec;68(6):968-9. doi: 10.1016/j.eururo.2015.07.050. Epub 2015 Aug 13. No abstract available.

PMID:
26278806
11.

Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice.

Wetterauer C, Vlajnic T, Schüler J, Gsponer JR, Thalmann GN, Cecchini M, Schneider J, Zellweger T, Pueschel H, Bachmann A, Ruiz C, Dirnhofer S, Bubendorf L, Rentsch CA.

Prostate. 2015 May;75(6):585-92. doi: 10.1002/pros.22939. Epub 2015 Jan 13.

PMID:
25585936
12.

Incidental prostate cancer prevalence at radical cystoprostatectomy--importance of the histopathological work-up.

Wetterauer C, Weibel M, Gsponer JR, Vlajnic T, Zellweger T, Bütikofer S, Müller G, Püschel H, Bachmann A, Gasser TC, Bubendorf L, Rentsch CA.

Virchows Arch. 2014 Dec;465(6):629-36. doi: 10.1007/s00428-014-1656-9. Epub 2014 Oct 1.

PMID:
25269630
13.

MED12 overexpression is a frequent event in castration-resistant prostate cancer.

Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.

Endocr Relat Cancer. 2014 Aug;21(4):663-75. doi: 10.1530/ERC-14-0171. Epub 2014 Jun 17.

14.

Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.

Ghadjar P, Oesch SL, Rentsch CA, Isaak B, Cihoric N, Manser P, Thalmann GN, Aebersold DM.

Radiat Oncol. 2014 May 28;9:122. doi: 10.1186/1748-717X-9-122.

15.

Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, Thalmann GN.

Eur Urol. 2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.

PMID:
24674149
16.

Characterization and clinical relevance of ALDHbright populations in prostate cancer.

Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.

Clin Cancer Res. 2013 Oct 1;19(19):5361-71. doi: 10.1158/1078-0432.CCR-12-2857. Epub 2013 Aug 22.

17.

Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease.

Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, Ruiz C.

Endocr Relat Cancer. 2013 May 21;20(3):403-13. doi: 10.1530/ERC-12-0402. Print 2013 Jun.

18.

BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model.

Rentsch CA, Biot C, Gsponer JR, Bachmann A, Albert ML, Breban R.

PLoS One. 2013;8(2):e56327. doi: 10.1371/journal.pone.0056327. Epub 2013 Feb 25.

19.

Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols.

Müller G, Bonkat G, Rieken M, Wyler SF, Bubendorf L, Püschel H, Gasser TC, Bachmann A, Rentsch CA.

Urology. 2013 Apr;81(4):837-42. doi: 10.1016/j.urology.2012.10.068. Epub 2013 Feb 6.

PMID:
23395126
20.

Deep clonal profiling of formalin fixed paraffin embedded clinical samples.

Holley T, Lenkiewicz E, Evers L, Tembe W, Ruiz C, Gsponer JR, Rentsch CA, Bubendorf L, Stapleton M, Amorese D, Legendre C, Cunliffe HE, McCullough AE, Pockaj B, Craig D, Carpten J, Von Hoff D, Iacobuzio-Donahue C, Barrett MT.

PLoS One. 2012;7(11):e50586. doi: 10.1371/journal.pone.0050586. Epub 2012 Nov 30.

Supplemental Content

Loading ...
Support Center